The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve Health
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve Health
批准号:
10414809
负责人:
Matthew D Ringel
金额:
$462.14万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-06-29 至 2023-10-31
关键词:
AddressAdoptedAdoptionBiomedical ResearchChild HealthChildhoodClinicClinical SciencesCollaborationsCommunitiesCompetenceDataData AnalyticsData ScienceDevelopmentDisciplineEducationEnvironmentFacultyFoundationsGoalsGovernmentGrantHealthHealth systemIndividualIndustryInformaticsInformation DisseminationInstitutesKnowledgeLongevityMethodologyMethodsMissionMulti-Institutional Clinical TrialOhioParticipantPathway interactionsPatientsPediatric HospitalsPopulationProcessPublicationsResearchResearch InfrastructureResearch MethodologyResearch PersonnelResearch TrainingResourcesRoleScienceScientistSecureSystemTimeTrainingTraining ProgramsTraining SupportTraining and EducationTranslational ResearchTranslationsUniversitiesVisionWorkWorkforce Developmentbasecareercareer developmentclinical centercollegedata sharingdata to knowledgeeducation resourceshealth inequalitiesimprovedinnovationmembernovel strategiesprogramsresearch studyskill acquisitiontooltranslational approachtranslational pipeline
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Contact PD/PI: Jackson, Rebecca D
OVERVIEW
SUMMARY
Since our inception, the overarching mission of The Ohio State University’s Center for Clinical and
Translational Science (CCTS) has been ambitious: to advance today’s discoveries to improve health. We
do this by providing an integrated environment of clinical and translational science (CTS) resources, education,
and training pathways and by promoting transformative methodologic advances to catalyze and sustain
translational science innovation. In collaboration with our pediatric partner, Nationwide Children’s Hospital, we
have developed an aligned vision for translational biomedical science that has been transformative. To
continue with our mission, we propose to advance from catalyzing translational science innovation and team
science locally to facilitating meaningful clinical and translational science collaborations with
community, academic, industry, and government partners and with members of the CTSA Consortium.
We will enhance and expand the training, career development, and sustainability of a diverse CTS workforce
through the provision of comprehensive, accessible education resources and opportunities (Workforce
Development) and engage a broad range of stakeholders as partners in the full spectrum of translational
research as active team participants from study inception through dissemination of results (Collaboration and
Engagement). We will provide new approaches and resources to enhance inclusion of populations that have
traditionally been excluded or studied in isolation and support and enhance studies that span the translational
research spectrum by actively reducing barriers to research study participation and catalyzing the translation of
discoveries to the clinic and population and across the lifespan (Integration). Moreover, we will promote
innovation, quality, and efficiency to advance translational science through an integrated system of
translational research resources (Methods and Processes). Finally, we will embed informatics and data
analytic solutions across all programs in the OSU-CCTS and across the full spectrum of translational research
(Informatics) by integrating and interrogating research data within a secure data environment, develop and
adopt innovative methods and tools that facilitate research, and provide a critical foundation in data sciences
for the translational science workforce. Over the next 5 years, we will provide a robust research infrastructure
and comprehensive research training programs informed by local innovations and strengthened by the
adoption of best practices identified by the CTSA Consortium. By leveraging our interdisciplinary scientific
strengths, expertise, and perspectives, the OSU-CCTS will catalyze biomedical research translation. With a
commitment to experimentation, we will identify gaps and challenges, systematically develop and study
(demonstrate) new methods and approaches, and disseminate effective strategies and educational initiatives
that will transform clinical and translational science both locally and nationally.
Project Summary/Abstract Page 275
Contact PD/PI: Jackson, Rebecca D
期刊论文(302)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.clae.2021.101493
发表时间:
2022-08
期刊:
Contact lens & anterior eye : the journal of the British Contact Lens Association
影响因子:
--
作者:
[Fogt JS, Kerwin T, Wrabel C, Schomer C, Fogt N]
通讯作者:
Fogt N
DOI:
10.1158/2767-9764.crc-23-0233
发表时间:
2023-09-22
期刊:
Cancer research communications
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.31031/acam.2022.07.000660
发表时间:
2022
期刊:
Advances in complementary & alternative medicine
影响因子:
--
作者:
[Hani H, Souchereau R, Kachlan A, Harris H, Dufour J, Aurand A, Mageswaran P, Hyer M, Marras W]
通讯作者:
Marras W
DOI:
10.1002/emp2.12576
发表时间:
2021-10
期刊:
Journal of the American College of Emergency Physicians open
影响因子:
2.3
作者:
[Bischof JJ, Sylvester PJ, Frey JA, Stephens JA, Hammond B, Garmatter J, Hebert C, Caterino JM]
通讯作者:
Caterino JM
DOI:
10.1016/j.jbi.2021.103788
发表时间:
2021-06
期刊:
JOURNAL OF BIOMEDICAL INFORMATICS
影响因子:
4.5
作者:
[Coombes, Caitlin E., Liu, Xin, Abrams, Zachary B., Coombes, Kevin R., Brock, Guy]
通讯作者:
Brock, Guy
共 213 条
RCAN 1.4 metastasis suppressor in thyroid cancer
-
批准号:9973560
-
项目类别:
-
资助金额:$45.25万
-
财政年份:2020
-
负责人:Matthew D Ringel
-
依托单位:
RCAN 1.4 metastasis suppressor in thyroid cancer
-
批准号:10604328
-
项目类别:
-
资助金额:$44.53万
-
财政年份:2020
-
负责人:Matthew D Ringel
-
依托单位:
RCAN 1.4 metastasis suppressor in thyroid cancer
-
批准号:10400004
-
项目类别:
-
资助金额:$44.34万
-
财政年份:2020
-
负责人:Matthew D Ringel
-
依托单位:
Role of p21-activated kinases in thyroid cancer
-
批准号:10377551
-
项目类别:
-
资助金额:$36.76万
-
财政年份:2018
-
负责人:Matthew D Ringel
-
依托单位:
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
-
批准号:8741949
-
项目类别:
-
资助金额:$216.2万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
Developing Combination Therapies for Medullary Thyroid Cancer
-
批准号:8588547
-
项目类别:
-
资助金额:$28.39万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE
-
批准号:8548721
-
项目类别:
-
资助金额:$215.05万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
Integrated Clinicopathology and Biorespository Core
-
批准号:8588551
-
项目类别:
-
资助金额:$27.9万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
Biostatistics Core
-
批准号:8588552
-
项目类别:
-
资助金额:$14.08万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
Administrative Core
-
批准号:8588554
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2013
-
负责人:Matthew D Ringel
-
依托单位:
RCAN1 in Thyroid Cancer Progression
-
批准号:8235810
-
项目类别:
-
资助金额:$33.59万
-
财政年份:2011
-
负责人:Matthew D Ringel
-
依托单位:
RCAN1 in Thyroid Cancer Progression
-
批准号:8403904
-
项目类别:
-
资助金额:$31.35万
-
财政年份:2011
-
负责人:Matthew D Ringel
-
依托单位:
RCAN1 in Thyroid Cancer Progression
-
批准号:8784195
-
项目类别:
-
资助金额:$33.07万
-
财政年份:2011
-
负责人:Matthew D Ringel
-
依托单位:
RCAN1 in Thyroid Cancer Progression
-
批准号:8108692
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2011
-
负责人:Matthew D Ringel
-
依托单位:
Genetic and Signaling Pathways in Epithelial Thyroid Cancer
-
批准号:8145140
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
Administrative Core
-
批准号:8506025
-
项目类别:
-
资助金额:$11.37万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
p21 Activated Kinase in Thyroid Cancer
-
批准号:9041531
-
项目类别:
-
资助金额:$39.31万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
Genetic and Signaling Pathways in Epithelial Thyroid Cancer
-
批准号:8064255
-
项目类别:
-
资助金额:$224.77万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
Genetic and Signaling Pathways in Epithelial Thyroid Cancer
-
批准号:9246457
-
项目类别:
-
资助金额:$229.72万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
Genetic and Signaling Pathways in Epithelial Thyroid Cancer
-
批准号:9041526
-
项目类别:
-
资助金额:$228.92万
-
财政年份:2008
-
负责人:Matthew D Ringel
-
依托单位:
海外基金